Loading…
Reported covered position: HIV Medicine Association Policy Officer
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
WINGMAN Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
WINGMAN Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2017 · fourth_quarter · Q4
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Source: Senate LDA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
WINGMAN Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
WINGMAN Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Preventing Antibiotic Resistance Act of 2017
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Preventing Antibiotic Resistance Act of 2017
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Preventing Antibiotic Resistance Act of 2017
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Preventing Antibiotic Resistance Act of 2017
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Antibiotic Development to Advance Patient Treatment Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Antibiotic Development to Advance Patient Treatment Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
DISARM Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
DISARM Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
PATH Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
PATH Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Preventing Antibiotic Resistance Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Preventing Antibiotic Resistance Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2017 · third_quarter · Q3
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2017 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2017 · first_quarter · Q1
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · fourth_quarter · Q4
Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).
Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · third_quarter · Q3
Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · second_quarter · Q2
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · third_quarter · Q3
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · second_quarter · Q2
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · first_quarter · Q1
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · fourth_quarter · Q4
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · third_quarter · Q3
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · second_quarter · Q2
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · fourth_quarter · Q4
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · third_quarter · Q3
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · second_quarter · Q2
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · first_quarter · Q1
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · third_quarter · Q3
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR); PDUFA
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2012 · first_quarter · Q1
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · third_quarter · Q3
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · second_quarter · Q2
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · fourth_quarter · Q4
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · third_quarter · Q3
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Medical Liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnecessary regulatory burdens placed on medical research; laboratory developed tests; Comparative effectiveness research; and Support for evidence-based decision making.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · second_quarter · Q2
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnnecessary regulatory burdens placed on medical research; laboratory developed tests; and Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advance Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administraton and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · first_quarter · Q1
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance (STAAR) Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens places on medical research; Support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · Q4
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquistion Program; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · third_quarter · Q3
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR); PDUFA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; and point-of-care diagnostic tests.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Depatment of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)